These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 29269377

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells.
    Niu W, Wang B, Zhang Y, Wang C, Cao J, Li J, He Y, Lei P.
    Front Immunol; 2024 Nov 15; 15():1433679. PubMed ID: 39086477
    [Abstract] [Full Text] [Related]

  • 24. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
    Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA.
    J Exp Med; 2013 Jun 03; 210(6):1125-35. PubMed ID: 23712432
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R.
    J Immunother Cancer; 2019 Jan 25; 7(1):19. PubMed ID: 30683154
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2.
    Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B.
    Cancer Res; 2003 Feb 01; 63(3):600-7. PubMed ID: 12566302
    [Abstract] [Full Text] [Related]

  • 31. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
    Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S.
    Mol Ther; 2013 Aug 01; 21(8):1611-20. PubMed ID: 23732988
    [Abstract] [Full Text] [Related]

  • 32. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity.
    Akai M, Noma K, Kato T, Nishimura S, Matsumoto H, Kawasaki K, Kunitomo T, Kobayashi T, Nishiwaki N, Kashima H, Kikuchi S, Ohara T, Tazawa H, Choyke PL, Kobayashi H, Fujiwara T.
    Br J Cancer; 2024 Jun 01; 130(10):1647-1658. PubMed ID: 38555315
    [Abstract] [Full Text] [Related]

  • 33. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO, L'Huillier A, Armington S, Mottershead C, Filippova EV, Coder BD, Petit RG, Princiotta MF.
    Cancer Res; 2018 Sep 15; 78(18):5340-5348. PubMed ID: 30026324
    [Abstract] [Full Text] [Related]

  • 34. Immunogene therapy.
    Lichtor T, Glick RP.
    Adv Exp Med Biol; 2012 Sep 15; 746():151-65. PubMed ID: 22639166
    [Abstract] [Full Text] [Related]

  • 35. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, Zhang B, Shi G, Zhang Y, Zhang Y, Huang A, Kuang Y, Cheng P.
    Acta Biomater; 2021 Nov 15; 135():567-581. PubMed ID: 34506976
    [Abstract] [Full Text] [Related]

  • 36. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
    Muralidhar A, Gamat-Huber M, Vakkalanka S, McNeel DG.
    J Immunother Cancer; 2024 May 20; 12(5):. PubMed ID: 38772685
    [Abstract] [Full Text] [Related]

  • 37. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
    Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, Ellenhorn JD.
    Cancer Immunol Immunother; 2007 Aug 20; 56(8):1193-205. PubMed ID: 17219151
    [Abstract] [Full Text] [Related]

  • 38. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
    Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG.
    Cancer Immunol Immunother; 2008 Nov 20; 57(11):1635-45. PubMed ID: 18386000
    [Abstract] [Full Text] [Related]

  • 39. Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.
    Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D.
    Mol Med; 2001 Jul 20; 7(7):461-9. PubMed ID: 11683371
    [Abstract] [Full Text] [Related]

  • 40. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.
    Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA.
    J Clin Invest; 2006 Jul 20; 116(7):1955-62. PubMed ID: 16794736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.